Monocytic myeloid-derived suppressor cells in chronic lymphocytic leukemia patients: a single center experience

References

• Rassenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008;112(5):1923–1930.
   PubMed Web of Science ®Google Scholar
• Zahran AM, Rayan A, Fakhry H, et al. Pretreatment detection of circulating and tissue CD133+ CD44+ cancer stem cells as a prognostic factor affecting the outcomes in Egyptian patients with colorectal cancer. Cancer Manag Res. 2019;11:1237–1248.
   PubMed Web of Science ®Google Scholar
• Zahran AM, Aly SS, Rayan A, El-Badawy O, et al. Survival outcomes of CD34+ CD38− LSCs and their expression of CD123 in adult AML patients. Oncotarget. 2018;9(75):34056.
   PubMedGoogle Scholar
• Zahran AM, Ashmawy AM, Rayan A, et al. Frequency and implications of natural killer and natural killer T cells in hepatocellular carcinoma. Egypt J Immunol. 2018;25(2):45–52.
   PubMedGoogle Scholar
• Zahran AM, Saleh MMF, Sayed MM, et al. Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia. Cancer Biomark. 2018;22(3):587–595.
   PubMed Web of Science ®Google Scholar
• Parker KH, Beury DW, Ostrand-Rosenberg S. Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. Adv Cancer Res. 2015;128:95–139.
   PubMed Web of Science ®Google Scholar
• Zahran AM, Abdel-Rahim MH, Refaat A, et al. Circulating hematopoietic stem cells, endothelial progenitor cells and cancer stem cells in hepatocellular carcinoma patients: contribution to diagnosis and prognosis. Acta Oncol. 2019;59(1):33–39.
   PubMedGoogle Scholar
• Farren T, Giustiniani J, Liu F-T, et al. Differential and tumor specific expression of CD160 in B-cell malignancies. Blood. 2011;118(8):2174–2183.
   PubMed Web of Science ®Google Scholar
• Zahran AM, Nafady-Hego H, Mansor SG, et al. Increased frequency and FOXP3 expression of human CD8+ CD25High + T lymphocytes and its relation to CD4 regulatory T cells in patients with hepatocellular carcinoma. Human Immunol. 2019;80(7):510–516.
   PubMed Web of Science ®Google Scholar
• Hassan EA, Ahmed EH, Nafee AM, et al. Regulatory T cells, IL10 and IL6 in HCV related hepatocellular carcinoma after transarterial chemoembolization (TACE). Egypt J Immunol. 2019;26(1):69–78.
   PubMedGoogle Scholar
• Lim HX, Hong H-J, Cho D, et al. IL-18 enhances immunosuppressive responses by promoting differentiation into monocytic myeloid-derived suppressor cells. J Immunol. 2014;193(11):5453–5460.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–174.
   PubMed Web of Science ®Google Scholar
• Hetta HF, Zahran AM, Mansor SG, et al. Frequency and Implications of myeloid‐derived suppressor cells and lymphocyte subsets in Egyptian patients with hepatitis C virus‐related hepatocellular carcinoma. J Med Virol. 2019;91(7):1319–1328.
   PubMed Web of Science ®Google Scholar
• Lindau D, Gielen P, Kroesen M, et al. The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013;138(2):105–115.
   PubMed Web of Science ®Google Scholar
• Poschke I, Kiessling R. On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol. 2012;144(3):250–268.
   PubMed Web of Science ®Google Scholar
• Jitschin R, Braun M, Büttner M, et al. CLL-cells induce IDOhi CD14+ HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood. 2014;124(5):750–760.
   PubMed Web of Science ®Google Scholar
• Botta C, Gullà A, Correale P, et al. Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. Front Oncol. 2014;4:348.
   PubMedGoogle Scholar
• Sun H, Li Y, Zhang Z-f, et al. Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia. Int J Hematol. 2015;102(5):579–586.
   PubMed Web of Science ®Google Scholar
• Gabitass RF, Annels NE, Stocken DD, et al. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011;60(10):1419–1430.
   PubMed Web of Science ®Google Scholar
• Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. ASH Educ Prog Book. 2009;2009:523–531.
   Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines. Blood. 2008;111(12):5446–5456.
   PubMed Web of Science ®Google Scholar
• Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Investig. 2007;117(5):1137–1146.
   PubMed Web of Science ®Google Scholar
• Tamadaho RS, Hoerauf A, Layland LE. Immunomodulatory effects of myeloid-derived suppressor cells in diseases: role in cancer and infections. Immunobiology. 2017;222:432–442.
   PubMedGoogle Scholar
• Ostrand-Rosenberg S, Fenselau C. Myeloid-derived suppressor cells: immune-suppressive cells that impair antitumor immunity and are sculpted by their environment. J Immunol. 2018;200(2):422–431.
   PubMed Web of Science ®Google Scholar
• Marx J. Cancer’s bulwark against immune attack: MDS cells. Am Assoc Adv Sci. 2008;319(5860):154–156.
   Google Scholar
• Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182(8):4499–4506.
   PubMed Web of Science ®Google Scholar
• Tcyganov E, Mastio J, Chen E, et al. Plasticity of myeloid-derived suppressor cells in cancer. Curr Opin Immunol. 2018;51:76–82.
   PubMed Web of Science ®Google Scholar
• Tadmor T. Monocytes, monocytic myeloid derived suppressor cells and lymphoma: how tight is the knot of the tie? J Leuk. 2013;01(04)
   Google Scholar
• Liu J, Zhou Y, Huang Q, et al. CD14+ HLA-DRlow/-expression: a novel prognostic factor in chronic lymphocytic leukemia. Oncol Lett. 2015;9(3):1167–1172.
   PubMed Web of Science ®Google Scholar
• Mizukoshi E, Yamashita T, Arai K, et al. Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. Cancer Immunol Immunother. 2016;65(6):715–725.
   PubMed Web of Science ®Google Scholar
• Najjar YG, Finke JH. Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol. 2013;3:49.
   PubMedGoogle Scholar
• Yu J, Du W, Yan F, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013;190(7):3783–3797.
   PubMed Web of Science ®Google Scholar
• Tadmor T, Fell R, Polliack A, et al. Absolute monocytosis at diagnosis correlates with survival in diffuse large B‐cell lymphoma—possible link with monocytic myeloid‐derived suppressor cells. Hematol Oncol. 2013;31(2):65–71.
   PubMed Web of Science ®Google Scholar
• Lin Y, Gustafson MP, Bulur PA, et al. Immunosuppressive CD14+ HLA-DRlow/− monocytes in B-cell non-Hodgkin lymphoma. Blood. 2011;117(3):872–881.
   PubMed Web of Science ®Google Scholar
• Wu C, Wu X, Liu X, et al. Prognostic significance of monocytes and monocytic myeloid-derived suppressor cells in diffuse large B-cell lymphoma treated with R-CHOP. Cell Physiol Biochem. 2016;39(2):521–530.
   PubMedGoogle Scholar
• Gustafson MP, Abraham RS, Lin Y, et al. Association of an increased frequency of CD14+ HLA‐DRlo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). Br J Haematol. 2012;156(5):674–676.
   PubMed Web of Science ®Google Scholar